Literature DB >> 16753148

Polo-like kinase 1 regulates mitotic arrest after UV irradiation through dephosphorylation of p53 and inducing p53 degradation.

Jie Chen1, Gu Dai, Yi-Qian Wang, Sheng Wang, Fei-Yan Pan, Bin Xue, Dong-Hong Zhao, Chao-Jun Li.   

Abstract

Ultraviolet (UV) irradiation can result in cell cycle arrest. The reactivation of Polo-like kinase 1 (Plk1) is necessary for cell cycle reentry. But the mechanism of how Plk1 regulates p53 in UV-induced mitotic arrest cells remained elusive. Here we find that UV treatment leads HEK293 cells to inverse changes of Plk1 and p53. Over-expression of Plk1 rescue UV-induced mitotic arrest cells by inhibiting p53 activation. Plk1 could also inhibit p53 phosphorylation at Ser15, thus facilitates its nuclear export and degradation. Further examination shows that Plk1, p53 and Cdc25C can form a large complex. Plk1 could bind to the sequence-specific DNA-binding domain of p53 and active Cdc25C by hyperphosphorylation. These results hypothesize that Plk1 and Cdc25C participate in recovery the mitotic arrest through binding to the different domain of p53. Cdc25C may first be actived by Plk1, and then its phosphatase activity makes p53 dephosphorylated at Ser15.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16753148     DOI: 10.1016/j.febslet.2006.05.047

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy.

Authors:  Leo Studach; Wen-Horng Wang; Gregory Weber; Jiabin Tang; Ronald L Hullinger; Raphael Malbrue; Xiaoqi Liu; Ourania Andrisani
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

2.  Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.

Authors:  Nami Koida; Toshinori Ozaki; Hideki Yamamoto; Sayaka Ono; Tadayuki Koda; Kiyohiro Ando; Rintaro Okoshi; Takehiko Kamijo; Ken Omura; Akira Nakagawara
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

3.  Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.

Authors:  Travis L Schmit; Weixiong Zhong; Minakshi Nihal; Nihal Ahmad
Journal:  Cell Cycle       Date:  2009-09-02       Impact factor: 4.534

4.  pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.

Authors:  Danielle S W Benoit; Scott M Henry; Andrew D Shubin; Allan S Hoffman; Patrick S Stayton
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

Review 5.  The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?

Authors:  Guillermo de Cárcer
Journal:  Genes (Basel)       Date:  2019-03-11       Impact factor: 4.096

6.  p53 modifications: exquisite decorations of the powerful guardian.

Authors:  Yanqing Liu; Omid Tavana; Wei Gu
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 6.216

7.  Mitotic Kinases and p53 Signaling.

Authors:  Geun-Hyoung Ha; Eun-Kyoung Yim Breuer
Journal:  Biochem Res Int       Date:  2012-07-19

Review 8.  Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation.

Authors:  Brian Geier; Dias Kurmashev; Raushan T Kurmasheva; Peter J Houghton
Journal:  Front Oncol       Date:  2015-08-26       Impact factor: 6.244

Review 9.  Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.

Authors:  Frank Louwen; Juping Yuan
Journal:  Oncotarget       Date:  2013-07

Review 10.  Polo-like kinase-1 in DNA damage response.

Authors:  Sun-Yi Hyun; Hyo-In Hwang; Hyo-In Hwan; Young-Joo Jang
Journal:  BMB Rep       Date:  2014-05       Impact factor: 4.778

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.